mTOR as a target for therapy of renal cancer.
Hudes
Gary R
GR
Genitourinary Malignancies Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols; D002292:Carcinoma, Renal Cell; D016503:Drug Delivery Systems / Q000379:methods*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007680:Kidney Neoplasms / Q000737:chemistry / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis; D011494:Protein Kinases / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D058570:TOR Serine-Threonine Kinases
D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases